---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000075"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:59:38.061409+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual

## Summary
- Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.
- Enrollment slower than anticipated due to emergence of new alternative treatment options.
- Interest among investigators remains high but company is reallocating resources to other pipeline programs.
- No financial impact or guidance changes disclosed in the filing.

## SEC filing metadata
- accession: 0001737287-24-000075
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000075/0001737287-24-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000075/allo-20241111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000075
- JSON: https://secwatch.observer/filing/0001737287-24-000075.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.